Background Athletes report using cannabidiol (CBD), a non-intoxicating constituent of Cannabis sativa L., to enhance post-exercise recovery and manage other health conditions (e.g., poor sleep, anxiety, concussion). However, whether CBD influences performance-related outcomes remains unclear. This study investigated the acute effects of a low, nutraceutical (50 mg) and moderate, therapeutic (300 mg) dose of CBD on physiological and subjective responses to endurance exercise in trained runners. Results A randomised double-blind, placebo-controlled, crossover clinical trial was conducted at the University of Sydney between 24th October 2022 and 4th March 2024. Twenty-five participants (16 male; <InlineEquation ID="IEq1"> <EquationSource Format="TEX">${\dot{\text{V}}}$</EquationSource> <EquationSource Format="MATHML"><math> <mover accent="true"> <mtext>V</mtext> <mo>˙</mo> </mover> </math></EquationSource> </InlineEquation>O2max = 53.1 ± 7.5 mL·min kg−1) received either 0 (placebo), 50 or 300 mg CBD 1.5 h prior to completing a 60-min, submaximal intensity (~ 70% <InlineEquation ID="IEq2"> <EquationSource Format="TEX">${\dot{\text{V}}}$</EquationSource> <EquationSource Format="MATHML"><math> <mover accent="true"> <mtext>V</mtext> <mo>˙</mo> </mover> </math></EquationSource> </InlineEquation>O2max) treadmill run (RUN 1), followed by an incremental run to volitional exhaustion (RUN 2). Neither dose of CBD altered subjective responses (i.e., affective valence, enjoyment, perceived exertion, pain) during RUN 1, nor enjoyment, mood or anxiety following RUN 1 and 2 (p’s > 0.05). CBD also had a limited effect on exercise physiology and performance, with heart rate, exercise efficiency (i.e., <InlineEquation ID="IEq3"> <EquationSource Format="TEX">${\dot{\text{V}}}$</EquationSource> <EquationSource Format="MATHML"><math> <mover accent="true"> <mtext>V</mtext> <mo>˙</mo> </mover> </math></EquationSource> </InlineEquation>O2), <InlineEquation ID="IEq4"> <EquationSource Format="TEX">${\dot{\text{V}}}$</EquationSource> <EquationSource Format="MATHML"><math> <mover accent="true"> <mtext>V</mtext> <mo>˙</mo> </mover> </math></EquationSource> </InlineEquation>O2peak and time to exhaustion (TTE) unchanged relative to placebo (p’s > 0.05). However, 300 mg CBD decreased the respiratory exchange ratio during RUN 1 (p = 0.030) and 50 mg CBD increased blood glucose upon cessation of RUN 2 (p = 0.003), compared to placebo. There was no effect of either dose on plasma concentrations of muscle damage markers, creatine and myoglobin (p’s > 0.05), but a Treatment x Time x Sex interaction was identified for the gastrointestinal barrier function marker, lipopolysaccharide, with post hoc analyses revealing higher concentrations in females Post RUN 2 on 50 mg (p = 0.032), but not 300mg CBD (p = 1.000), compared to placebo. Conclusions CBD (50 mg, 300 mg; acute) does not appear to alter the subjective experience of submaximal intensity exercise, impact endurance performance (i.e., TTE) or have compelling effects on physiological responses to exercise. Use of CBD by athletes is, therefore, unlikely to be ergolytic or ergogenic at low to moderate doses. Trial registration The trial was approved by the Sydney Local Health District’s Human Research Ethics Committee (2021/ ETH11945; X21-0392) and registered prospectively with the Australia and New Zealand Clinical Trials Registry (ACTRN12622000717752).

The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial

期刊论文
出版模式：

开放获取
发表日期：

2025年8月21日

查看全文

Ayshe Sahinovic,
Namson S. Lau,
Angelo Sabag,
Rebecca Gordon,
Amanda J. Cox,
Katie Walker,
Christopher Irwin,
Ben Desbrow,
Nathan Johnson,
Paul J. Austin,
Paul Haber,
Iain S. McGregor,
Danielle McCartney

摘要

Background

Athletes report using cannabidiol (CBD), a non-intoxicating constituent of Cannabis sativa L., to enhance post-exercise recovery and manage other health conditions (e.g., poor sleep, anxiety, concussion). However, whether CBD influences performance-related outcomes remains unclear. This study investigated the acute effects of a low, nutraceutical (50 mg) and moderate, therapeutic (300 mg) dose of CBD on physiological and subjective responses to endurance exercise in trained runners.

Results

A randomised double-blind, placebo-controlled, crossover clinical trial was conducted at the University of Sydney between 24th October 2022 and 4th March 2024. Twenty-five participants (16 male; ${\dot{\text{V}}}$ $\dot{V}$ O_2max = 53.1 ± 7.5 mL·min kg⁻¹) received either 0 (placebo), 50 or 300 mg CBD 1.5 h prior to completing a 60-min, submaximal intensity (~ 70% ${\dot{\text{V}}}$ $\dot{V}$ O_2max) treadmill run (RUN 1), followed by an incremental run to volitional exhaustion (RUN 2). Neither dose of CBD altered subjective responses (i.e., affective valence, enjoyment, perceived exertion, pain) during RUN 1, nor enjoyment, mood or anxiety following RUN 1 and 2 (p’s > 0.05). CBD also had a limited effect on exercise physiology and performance, with heart rate, exercise efficiency (i.e., ${\dot{\text{V}}}$ $\dot{V}$ O₂), ${\dot{\text{V}}}$ $\dot{V}$ O_2peak and time to exhaustion (TTE) unchanged relative to placebo (p’s > 0.05). However, 300 mg CBD decreased the respiratory exchange ratio during RUN 1 (p = 0.030) and 50 mg CBD increased blood glucose upon cessation of RUN 2 (p = 0.003), compared to placebo. There was no effect of either dose on plasma concentrations of muscle damage markers, creatine and myoglobin (p’s > 0.05), but a Treatment x Time x Sex interaction was identified for the gastrointestinal barrier function marker, lipopolysaccharide, with post hoc analyses revealing higher concentrations in females Post RUN 2 on 50 mg (p = 0.032), but not 300mg CBD (p = 1.000), compared to placebo.

Conclusions

CBD (50 mg, 300 mg; acute) does not appear to alter the subjective experience of submaximal intensity exercise, impact endurance performance (i.e., TTE) or have compelling effects on physiological responses to exercise. Use of CBD by athletes is, therefore, unlikely to be ergolytic or ergogenic at low to moderate doses.

Trial registration

The trial was approved by the Sydney Local Health District’s Human Research Ethics Committee (2021/ ETH11945; X21-0392) and registered prospectively with the Australia and New Zealand Clinical Trials Registry (ACTRN12622000717752).